
Sign up to save your podcasts
Or


Welcome back to another insightful clip of Market Mondays! In this clip hosts, Troy Millings and Ian Dunlap, dive deep into the recent movements in Eli Lilly's stock. With a 26% drop from its peak of $972 to $718, many investors are questioning whether this is a cause for alarm or a golden opportunity to buy.
Ian and Troy break down the situation, examining the factors behind the stock's recent performance. They consider the influence of political lobbying and the potential impact of RFK's policies on the pharmaceutical space. The insight provided includes a crucial lesson on understanding quarterly ranges and recognizing when stock prices revert to their normal range after periods of exuberance.
Discussing the pharmaceutical giants Eli Lilly and Novo Nordisk, our hosts highlight the strengths of both companies but ultimately favor Eli Lilly for its better management, competitive advantages, and robust product portfolio. Despite recent earnings misses on key products like Zip Hound and Mounjaro, Ian and Troy emphasize that Eli Lilly's diversified portfolio, which includes one of only two Alzheimer’s drugs on the market, solidifies its place as a top-tier company in the industry.
Troy and Ian also share valuable investment strategies, advising against buying assets near their all-time highs and highlighting the importance of patience and long-term holding. They encourage viewers to do their homework, understand the competitive advantages of top companies, and take advantage of market pullbacks rather than succumbing to fear.
Towards the end, the discussion turns philosophical, touching on broader themes of financial responsibility, the importance of long-term thinking, and the pitfalls of short-term trading. Ian passionately urges viewers to hold their investments for at least five years to truly reap the benefits and avoid the common mistakes of impulsive selling.
Whether you are a seasoned investor or just starting on your investment journey, this episode of Market Mondays Medium is packed with practical advice, deep insights, and thought-provoking discussions. Don't forget to like, subscribe, and hit the notification bell to stay updated with all our latest episodes.
**Hashtags**:
#MarketMondays #EliLilly #StockMarket #Investing #Finance #Pharmaceuticals #LongTermInvesting #IanDunlap #TroyMillings #InvestmentStrategy #StockAnalysis #BuyTheDip #FinancialEducation #NovoNordisk #WealthBuilding #HoldFor5Years #PoliticalLobbying #AlzheimersDrug #EarningsReport #InvestmentTips #AmericanBusiness
See omnystudio.com/listener for privacy information.
By iHeartPodcasts4.9
78137,813 ratings
Welcome back to another insightful clip of Market Mondays! In this clip hosts, Troy Millings and Ian Dunlap, dive deep into the recent movements in Eli Lilly's stock. With a 26% drop from its peak of $972 to $718, many investors are questioning whether this is a cause for alarm or a golden opportunity to buy.
Ian and Troy break down the situation, examining the factors behind the stock's recent performance. They consider the influence of political lobbying and the potential impact of RFK's policies on the pharmaceutical space. The insight provided includes a crucial lesson on understanding quarterly ranges and recognizing when stock prices revert to their normal range after periods of exuberance.
Discussing the pharmaceutical giants Eli Lilly and Novo Nordisk, our hosts highlight the strengths of both companies but ultimately favor Eli Lilly for its better management, competitive advantages, and robust product portfolio. Despite recent earnings misses on key products like Zip Hound and Mounjaro, Ian and Troy emphasize that Eli Lilly's diversified portfolio, which includes one of only two Alzheimer’s drugs on the market, solidifies its place as a top-tier company in the industry.
Troy and Ian also share valuable investment strategies, advising against buying assets near their all-time highs and highlighting the importance of patience and long-term holding. They encourage viewers to do their homework, understand the competitive advantages of top companies, and take advantage of market pullbacks rather than succumbing to fear.
Towards the end, the discussion turns philosophical, touching on broader themes of financial responsibility, the importance of long-term thinking, and the pitfalls of short-term trading. Ian passionately urges viewers to hold their investments for at least five years to truly reap the benefits and avoid the common mistakes of impulsive selling.
Whether you are a seasoned investor or just starting on your investment journey, this episode of Market Mondays Medium is packed with practical advice, deep insights, and thought-provoking discussions. Don't forget to like, subscribe, and hit the notification bell to stay updated with all our latest episodes.
**Hashtags**:
#MarketMondays #EliLilly #StockMarket #Investing #Finance #Pharmaceuticals #LongTermInvesting #IanDunlap #TroyMillings #InvestmentStrategy #StockAnalysis #BuyTheDip #FinancialEducation #NovoNordisk #WealthBuilding #HoldFor5Years #PoliticalLobbying #AlzheimersDrug #EarningsReport #InvestmentTips #AmericanBusiness
See omnystudio.com/listener for privacy information.

78,700 Listeners

23,787 Listeners

2,534 Listeners

6,451 Listeners

8,760 Listeners

6,803 Listeners

10,347 Listeners

8,329 Listeners

14,237 Listeners

15,679 Listeners

10,949 Listeners

9,085 Listeners

11,835 Listeners

4,047 Listeners

7,417 Listeners

9,812 Listeners

10,518 Listeners

2,052 Listeners

1,651 Listeners

1,014 Listeners

1,934 Listeners

163 Listeners

310 Listeners

1,924 Listeners